Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Change in Accured Expenses: 2012-2024

Historic Change in Accured Expenses for Ocular Therapeutix (OCUL) over the last 13 years, with Dec 2024 value amounting to $3.6 million.

  • Ocular Therapeutix's Change in Accured Expenses fell 4.05% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 million, marking a year-over-year increase of 501.21%. This contributed to the annual value of $3.6 million for FY2024, which is 370.63% up from last year.
  • According to the latest figures from FY2024, Ocular Therapeutix's Change in Accured Expenses is $3.6 million, which was up 370.63% from $773,000 recorded in FY2023.
  • Ocular Therapeutix's Change in Accured Expenses' 5-year high stood at $3.7 million during FY2021, with a 5-year trough of $773,000 in FY2023.
  • For the 3-year period, Ocular Therapeutix's Change in Accured Expenses averaged around $2.0 million, with its median value being $1.6 million (2022).
  • As far as peak fluctuations go, Ocular Therapeutix's Change in Accured Expenses slumped by 55.77% in 2022, and later spiked by 370.63% in 2024.
  • Yearly analysis of 5 years shows Ocular Therapeutix's Change in Accured Expenses stood at $2.3 million in 2020, then surged by 60.84% to $3.7 million in 2021, then tumbled by 55.77% to $1.6 million in 2022, then crashed by 52.98% to $773,000 in 2023, then surged by 370.63% to $3.6 million in 2024.